Compare Incyte Corporation (INCY) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs MasterCard Inc — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while MasterCard Inc trades at $546.79 (market cap $483.71B). The key difference: MasterCard Inc is far larger — about 20.9× Incyte Corporation's market cap, and MasterCard Inc pays a 0.64% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MA | |
|---|---|---|
Market Cap | $23.11B | $483.71B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $598.96 |
52-Week Low | $67.38 | $471.55 |
Enterprise Value | $19.13B | $494.45B |
Volume | — | 4,635,698 |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Mastercard (MA) trades at $543.6, down 1.44% on the day, with strong technical support near $540 and bullish moving average signals. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $4.60 exceeding expectations of $4.41. Revenue grew to $32.79B in 2025, and net income margin remains high at 45.88%. Analysts maintain a strong buy consensus with a $634.27 price target, reflecting 16.7% upside potential.
Outlook remains positive driven by payment volume growth and AI initiatives, but risks include competitive disruption from stablecoins and high valuation multiples. Institutional ownership trends show continued accumulation, supporting bullish sentiment. The stock's current price is within 5% of recent highs, indicating potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
